Margery Fischbein, managing director of the healthcare practice at Cassel Salpeter & Co., is a highly experienced investment banker and corporate executive with particular expertise in biotechnology and other sectors of the healthcare industry. Margery has worked with clients ranging in size from large multinational healthcare companies to small cap, emerging growth public and private biotechnology companies. Margery has also served as head of business development and strategy for two leading biotechnology companies.
Margery has successfully led numerous mergers and acquisitions, licensing, and public and private financing transactions for healthcare companies. She has also worked on strategic advisory and valuation projects for life sciences, medical technology, and healthcare IT/artificial intelligence companies.
Prior to joining Cassel Salpeter, Margery was Head of Healthcare Investment Banking for Seaport Global and FBR & Co., and Head of East Coast Biotechnology Investment Banking for JMP Securities. Margery held senior executive positions with Human Genome Sciences and ImClone Systems, who were leaders in their field until being acquired by GlaxoSmithKline and Eli Lilly and Company, respectively. Margery started her investment banking career at Lehman Brothers (where she rose to Senior Vice President) and was then a Managing Director of Investment Banking at JP Morgan Chase and Citigroup.
Currently, Margery serves on the Boards of Cytodel, Inc., EcoHealth Alliance, the Harvard Business School Club of Greater NY, the Harvard Business School Club of South Florida, and the Harvard Club of the Palm Beaches. Margery enjoys exercising, painting, and drawing and writing.
Margery earned a master’s in business administration from Harvard Business School and a bachelor’s degree from Harvard University.